Myriad ends lawsuit with GenebyGene, freeing it to market BRCA genetic tests outside North America
Update: Despite the U.S. Supreme Court ruling last year year, BRCA gene testing has continued to be an issue in the courts. But a patent infringement case between Myriad Genetics (Nasdaq: MYGN) and GenebyGene has been resolved and offers some guidance on the potential outcome of other cases in which Myriad is embroiled. The terms […]